Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.63)
# 192
Out of 5,090 analysts
125
Total ratings
56.14%
Success rate
30.79%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Reiterates: Buy | $6 | $1.60 | +276.18% | 3 | Dec 2, 2025 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $30 → $5 | $4.18 | +19.76% | 8 | Nov 17, 2025 | |
| KOD Kodiak Sciences | Maintains: Buy | $24 → $26 | $24.51 | +6.08% | 7 | Nov 17, 2025 | |
| IMUX Immunic | Maintains: Buy | $10 → $8 | $0.69 | +1,059.50% | 6 | Nov 14, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $52 → $56 | $39.45 | +41.95% | 13 | Nov 12, 2025 | |
| FBLG FibroBiologics | Maintains: Buy | $10 → $5 | $0.26 | +1,824.56% | 7 | Nov 5, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $20 → $26 | $14.64 | +77.60% | 11 | Oct 31, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Buy | $30 → $44 | $37.75 | +16.56% | 5 | Oct 28, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $72 → $88 | $81.91 | +7.44% | 2 | Oct 20, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $12 | $8.56 | +40.19% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $16 | $4.48 | +257.14% | 9 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $56 | $27.82 | +101.29% | 7 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.24 | +257.14% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $10 | $5.87 | +70.36% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $4.87 | +105.55% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $18.39 | +74.01% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $11.21 | +221.14% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $471.78 | -94.07% | 1 | Aug 22, 2023 |
Akebia Therapeutics
Dec 2, 2025
Reiterates: Buy
Price Target: $6
Current: $1.60
Upside: +276.18%
Adverum Biotechnologies
Nov 17, 2025
Downgrades: Neutral
Price Target: $30 → $5
Current: $4.18
Upside: +19.76%
Kodiak Sciences
Nov 17, 2025
Maintains: Buy
Price Target: $24 → $26
Current: $24.51
Upside: +6.08%
Immunic
Nov 14, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $0.69
Upside: +1,059.50%
Mineralys Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $52 → $56
Current: $39.45
Upside: +41.95%
FibroBiologics
Nov 5, 2025
Maintains: Buy
Price Target: $10 → $5
Current: $0.26
Upside: +1,824.56%
Phathom Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $20 → $26
Current: $14.64
Upside: +77.60%
Zenas BioPharma
Oct 28, 2025
Maintains: Buy
Price Target: $30 → $44
Current: $37.75
Upside: +16.56%
Tarsus Pharmaceuticals
Oct 20, 2025
Maintains: Buy
Price Target: $72 → $88
Current: $81.91
Upside: +7.44%
DiaMedica Therapeutics
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $8.56
Upside: +40.19%
Aug 14, 2025
Reiterates: Neutral
Price Target: $16
Current: $4.48
Upside: +257.14%
Aug 1, 2025
Maintains: Buy
Price Target: $48 → $56
Current: $27.82
Upside: +101.29%
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $2.24
Upside: +257.14%
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $5.87
Upside: +70.36%
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $4.87
Upside: +105.55%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $18.39
Upside: +74.01%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $11.21
Upside: +221.14%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $471.78
Upside: -94.07%